Replies to post #277005 on Anavex Life Sciences Corp (AVXL)

[JWC3]

Already ALZHEIMER’S is in the equation, FTD is merely another nut to crack now. Just making AD the target might confuse people. Keep it simple at first. Then be confusing when it needs to be.

[falconer66a]

Some unknown chemistry factor?

Wondering why they didn't choose Alzheimer's for Anavex3-71's maiden voyage.

I've pondered this, too. Given Anavex 3-71's greater activity, dosings in micrograms instead of milligrams, why wasn't it the company's lead, roll-out drug? Not only that, it seems to potentiate an even broader array of optimized downstream effects than blarcamesine.

I'm not concerned, however. The Anavex people know the involved biochemistries better than anyone not seeing all of the internal information they've generated, with both in vivo (in animals) and in vitro (in cultures in glassware) studies. Perhaps there are manufacturing things that need to be worked out with the drug.

Who knows? We'll be learning more about safety and efficacies when the drug is tested in people with frontotemporal dementia (FTD):
https://patientworthy.com/2020/06/01/anavex371-treatment-for-neurodegenerative-diseases/

[Gernee20]

quickest path to market...